Hosted on MSN
Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.
Novo Nordisk said Monday it would begin selling its Type 2 diabetes treatment Ozempic directly to consumers at $499 per month, half the U.S. list price of the medicine. It is just the latest direct-to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results